NEOHALER Device

SEEBRI NEOHALER: COPD symptom control in a practical device

The NEOHALER device, designed with your patients in mind

The SEEBRI™ NEOHALER®  bronchodilator for COPD

Soft whirring noise SEEBRI NEOHALER makes a distinct whirring noise to indicate the capsule has been placed in the chamber correctly.1



SEEBRI capsules containing glycopyrrolate inhalation powder for COPD.

Clear capsule After the inhalation is completed, patients are instructed to open the NEOHALER and examine the SEEBRI capsule. The clear capsule allows patients to visually confirm whether there is any medicine remaining in the capsule, giving them the flexibility to inhale any remaining dose.1

SEEBRI capsules are for oral inhalation only and should not be swallowed. SEEBRI capsules should be used with the NEOHALER device only.

It is important for patients to understand how to correctly administer SEEBRI capsules using the NEOHALER device, by following the patient Instructions for Use. Instruct patients that SEEBRI capsules should only be administered via the NEOHALER device and the NEOHALER device should not be used for administering other medications.


Reference:
1. SEEBRI NEOHALER [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017.

Important Safety Information & Indication

Important Safety Information

SEEBRI NEOHALER is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

SEEBRI NEOHALER should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, SEEBRI NEOHALER can produce paradoxical bronchospasm that may be life threatening. If paradoxical bronchospasm occurs following dosing with SEEBRI NEOHALER, it should be treated immediately with an inhaled, short-acting bronchodilator; SEEBRI NEOHALER should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with SEEBRI NEOHALER. If signs occur, discontinue immediately and institute alternative therapy. SEEBRI NEOHALER should be used with caution in patients with severe hypersensitivity to milk proteins.

SEEBRI NEOHALER should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥1% of patients taking SEEBRI NEOHALER, and occurring more frequently than in patients taking placebo, were upper respiratory tract infection (3.4% vs 2.3%), nasopharyngitis (2.1% vs 1.9%), oropharyngeal pain (1.8% vs 1.2%), urinary tract infection (1.4% vs 1.3%), and sinusitis (1.4% vs 0.7%).

SEEBRI capsules must not be swallowed as the intended effects on the lungs will not be obtained. SEEBRI capsules are only for oral inhalation and should only be used with the NEOHALER device.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for SEEBRI NEOHALER.

Indication

SEEBRITM NEOHALER® (glycopyrrolate) is an anticholinergic indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.